Hormonal
GLP-1 receptor agonists (specifically liraglutide) exert direct anti-inflammatory and chondroprotective effects in osteoarthritis by suppressing NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and downregulating cartilage-degrading enzymes (MMPs, ADAMTS), while promoting type II collagen synthesis.
Research shows that GLP-1 drugs may protect knee cartilage directly by reducing inflammation and stopping enzymes that break down joint tissue, in addition to helping you lose weight. This suggests these drugs might slow the progression of osteoarthritis, not just mask the pain.
preclinical, in vitro and in vivo studies demonstrate that liraglutide exerts anti- inflammatory and chondroprotective effects in OA. This agent suppresses the activation of nuclear factor kappa- light- chain- enhancer of activated B cells (NF-κB) and downstream cytokines, such as IL- 1β, IL- 6 and TNF-α; attenuates oxidative stress and downregulates cartilage- degrading enzymes, such as matrix metalloproteinase- 1 (MMP- 1), MMP- 3, MMP- 13 and A disintegrin and metalloproteinase with thrombospondin motifs- 4 and -5 (ADAMTS- 4/5), while promoting anabolic repair via enhanced type II collagen and aggrecan synthesis.
Why this rating
Based on preclinical, in vitro, and in vivo studies; human structural evidence is still emerging (STOP-KNEE OA trial).
Source
If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?
Francesco Ursini et al. · RMD Open · 2025
DOI 10.1136/rmdopen-2025-006025
More from this paper
- GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.Good
- GLP-1 receptor agonists reduce the incidence of knee surgeries and slow cartilage loss in patients with knee osteoarthritis and type 2 diabetes, as demonstrated in real-world observational cohorts.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →